SELLAS Life Sciences Group, Inc.
SLS
$7.68
-$0.30-3.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -29.46M | -26.86M | -25.94M | -26.26M | -27.13M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.85M | 2.55M | 2.47M | 2.34M | 2.16M |
| Change in Net Operating Assets | -1.56M | -4.08M | -7.15M | -7.44M | -8.75M |
| Cash from Operations | -28.17M | -28.39M | -30.62M | -31.36M | -33.71M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 56.35M | 35.78M | 31.95M | 47.57M | 43.76M |
| Repurchase of Common Stock | -527.00K | -527.00K | -64.00K | -64.00K | -64.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 51.04M | 51.04M | 22.03M | -- | -- |
| Cash from Financing | 106.87M | 86.30M | 53.91M | 47.51M | 43.69M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 78.70M | 57.91M | 23.29M | 16.15M | 9.98M |